GAMMA Investing LLC Purchases Shares of 1,532 Henry Schein, Inc. (NASDAQ:HSIC)

GAMMA Investing LLC purchased a new stake in Henry Schein, Inc. (NASDAQ:HSIC) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,532 shares of the company’s stock, valued at approximately $115,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. McGlone Suttner Wealth Management Inc. purchased a new stake in shares of Henry Schein in the fourth quarter valued at about $39,000. Baystate Wealth Management LLC raised its position in shares of Henry Schein by 2,500.0% in the third quarter. Baystate Wealth Management LLC now owns 520 shares of the company’s stock valued at $39,000 after buying an additional 500 shares during the last quarter. Neo Ivy Capital Management acquired a new position in shares of Henry Schein in the third quarter valued at approximately $46,000. Covestor Ltd raised its position in shares of Henry Schein by 22.8% in the third quarter. Covestor Ltd now owns 1,367 shares of the company’s stock valued at $102,000 after buying an additional 254 shares during the last quarter. Finally, Fifth Third Bancorp raised its position in shares of Henry Schein by 14.3% in the third quarter. Fifth Third Bancorp now owns 1,744 shares of the company’s stock valued at $129,000 after buying an additional 218 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Trading Up 0.4 %

NASDAQ HSIC opened at $73.13 on Monday. Henry Schein, Inc. has a 12 month low of $60.01 and a 12 month high of $82.63. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.67 and a quick ratio of 1.00. The company has a market capitalization of $9.40 billion, a price-to-earnings ratio of 23.22, a price-to-earnings-growth ratio of 1.81 and a beta of 0.87. The company’s fifty day moving average price is $74.17 and its two-hundred day moving average price is $72.42.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $0.66 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.04). Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The company had revenue of $3.02 billion for the quarter, compared to the consensus estimate of $3 billion. During the same quarter last year, the company earned $1.21 earnings per share. The company’s revenue was down 10.5% compared to the same quarter last year. As a group, research analysts predict that Henry Schein, Inc. will post 5.07 earnings per share for the current fiscal year.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the transaction, the insider now directly owns 209,562 shares in the company, valued at approximately $15,585,125.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Vice Chairman James P. Breslawski sold 2,907 shares of the firm’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $74.37, for a total value of $216,193.59. Following the transaction, the insider now directly owns 209,562 shares in the company, valued at approximately $15,585,125.94. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Bradford C. Connett sold 6,430 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the completion of the transaction, the chief executive officer now owns 73,108 shares in the company, valued at $5,430,462.24. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Barrington Research upped their price target on shares of Henry Schein from $82.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 28th. Piper Sandler upped their price target on shares of Henry Schein from $78.00 to $86.00 and gave the stock an “overweight” rating in a research report on Monday, February 26th. Jefferies Financial Group upped their price target on shares of Henry Schein from $74.00 to $81.00 and gave the stock a “hold” rating in a research report on Wednesday, March 6th. Leerink Partnrs reaffirmed a “market perform” rating on shares of Henry Schein in a research report on Monday, February 26th. Finally, SVB Leerink started coverage on shares of Henry Schein in a research report on Monday, February 26th. They issued a “market perform” rating and a $78.00 price objective for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $81.09.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.